STAT+: Fatal gene-editing trial in China raises ethics and oversight questions

STAT PlusNewsletterThe Readout Fatal gene-editing trial in China raises ethics and oversight questions Sanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJuly 24, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, a win for RFK Jr., as an FDA panel narrowly voted in favor of allowing compounding pharmacies to produce certain unregulated peptides. Also, in heart-wrenching detail, Science writes of the six-year-old girl who died in China after receiving an experimental, brain-directed CRISPR therapy. Advertisement The Readout’s taking a summer break next week, so we’ll see you in August! STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 23, 2026 STAT Plus: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides The Readout July 23, 2026 FDA panel confronting peptide controversy Advertisement The Readout July 22, 2026 STAT Plus: Pharma tries to tamp down broad China restrictions D.C. Diagnosis July 21, 2026 STAT Plus: Rare disease drugmakers try to avoid Trump price cuts Biotech July 21, 2026 STAT Plus: Broad Institute, partners unveil new initiative to develop gene therapies for rare diseases Subscriber Picks